Quick Answer
Editas Medicine, Inc. reported Total Revenue of $40.52 million for fiscal year 2025.
Editas Medicine, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $40.52M +25.4% |
$32.31M -58.6% |
$78.12M +296.3% |
$19.71M -22.8% |
$25.54M -71.8% |
$90.73M +341.9% |
| Revenue (ASC 606) | $40.52M +25.4% |
$32.31M -58.6% |
$78.12M +296.3% |
$19.71M -22.8% |
$25.54M -71.8% |
$90.73M +341.9% |
| Net Income | -$160.06M +32.5% |
-$237.09M -54.7% |
-$153.22M +30.5% |
-$220.43M -14.5% |
-$192.50M -66.0% |
-$115.98M +13.3% |
| Diluted EPS | -$1.80 +37.5% |
-$2.88 -42.6% |
-$2.02 +37.1% |
-$3.21 -12.6% |
-$2.85 -43.9% |
-$1.98 +26.1% |
| Total Assets | $186.53M -45.4% |
$341.59M -31.6% |
$499.15M -2.9% |
$514.32M -24.1% |
$677.48M +18.3% |
$572.60M +12.5% |
| Cash and Equivalents | $146.65M +11.5% |
$131.54M +6.4% |
$123.65M -12.6% |
$141.52M -30.5% |
$203.52M +45.7% |
$139.68M -41.4% |
| Long-Term Debt | $53.60M +2.2% |
$52.43M | $0.00 | — | — | — |
| Stockholders Equity | $27.29M -79.7% |
$134.27M -61.5% |
$349.10M -3.2% |
$360.68M -34.9% |
$553.64M +40.7% |
$393.59M +50.0% |
| R&D Expense | $89.95M -54.9% |
$199.25M +12.2% |
$177.65M +1.5% |
$174.96M +22.8% |
$142.51M -9.8% |
$158.00M +63.1% |
| Operating Income | -$160.01M +36.3% |
-$251.15M -48.5% |
-$169.18M +25.1% |
-$225.95M -17.0% |
-$193.15M -43.2% |
-$134.84M +4.3% |
| Shares Outstanding | 97.87M +18.3% |
82.73M +1.2% |
81.77M +18.8% |
68.85M +0.6% |
68.44M +9.4% |
62.56M +15.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $7.54M | +12265.6% | +110.8% |
| Revenue (ASC 606) | September 30, 2025 | $7.54M | +12265.6% | +110.8% |
| Net Income | September 30, 2025 | -$25.12M | +59.6% | +52.8% |
| Diluted EPS | September 30, 2025 | -$0.28 | +62.7% | +55.6% |
| Total Assets | September 30, 2025 | $201.75M | -38.4% | -4.2% |
| Cash and Equivalents | September 30, 2025 | $165.65M | +72.9% | +19.6% |
| Long-Term Debt | September 30, 2025 | $54.07M | — | +4.6% |
| Stockholders Equity | September 30, 2025 | $13.45M | -92.3% | -29.9% |
| R&D Expense | September 30, 2025 | $19.77M | -58.5% | +22.2% |
| Operating Income | September 30, 2025 | -$24.55M | +62.6% | +52.4% |
| Shares Outstanding | September 30, 2025 | 93.26M | +13.0% | +6.7% |
- Editas Medicine, Inc. reported Total Revenue of $40.52 million for fiscal year 2025.
- Editas Medicine, Inc. showed an increase of +25.4% in Total Revenue compared to the prior fiscal year.
- Editas Medicine, Inc. reported Revenue (ASC 606) of $40.52 million for fiscal year 2025.
- Editas Medicine, Inc. showed an increase of +25.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Editas Medicine, Inc. reported Net Income of -$160.06 million for fiscal year 2025.
- Editas Medicine, Inc. showed an increase of +32.5% in Net Income compared to the prior fiscal year.
- Editas Medicine, Inc. reported Diluted EPS of $1.80 per share (loss) for fiscal year 2025.
- Editas Medicine, Inc. showed an increase of +37.5% in Diluted EPS compared to the prior fiscal year.
- Editas Medicine, Inc. reported Total Assets of $186.53 million for fiscal year 2025.
- Editas Medicine, Inc. showed a decrease of -45.4% in Total Assets compared to the prior fiscal year.
- Editas Medicine, Inc. reported Cash and Equivalents of $146.65 million for fiscal year 2025.
- Editas Medicine, Inc. showed an increase of +11.5% in Cash and Equivalents compared to the prior fiscal year.
- Editas Medicine, Inc. reported Long-Term Debt of $53.60 million for fiscal year 2025.
- Editas Medicine, Inc. showed an increase of +2.2% in Long-Term Debt compared to the prior fiscal year.
- Editas Medicine, Inc. reported Stockholders Equity of $27.29 million for fiscal year 2025.
- Editas Medicine, Inc. showed a decrease of -79.7% in Stockholders Equity compared to the prior fiscal year.
- Editas Medicine, Inc. reported R&D Expense of $89.95 million for fiscal year 2025.
- Editas Medicine, Inc. showed a decrease of -54.9% in R&D Expense compared to the prior fiscal year.
- Editas Medicine, Inc. reported Operating Income of -$160.01 million for fiscal year 2025.
- Editas Medicine, Inc. showed an increase of +36.3% in Operating Income compared to the prior fiscal year.
- Editas Medicine, Inc. reported Shares Outstanding of 97.87 million shares for fiscal year 2025.
- Editas Medicine, Inc. showed an increase of +18.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: